Clinical trials: PET-CT
Kidney Cancer, Lymphomas
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
The aim of this study was to establish and optimize the [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy…
- Conditions
- Kidney Cancer, Lymphomas, Positron Emission Tomography
- Trial name
- NCT06148220
- Testing
- [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huashan Hospital
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Non Small Cell Lung Cancer
PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer
The goal of this study is to find the maximum tolerable dose of radiation that can be delivered combined with chemotherapy (carboplatin \& paclitaxel) in patients with stage III non-small cell lung cancer (NSCLC).
- Trial name
- NCT03099577
- Testing
- radiochemotherapy 1, radiochemotherapy 2, radiochemotherapy 3
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Glioma, Glioblastoma
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
It was previously shown that 18F-DOPA PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been…
- Trial name
- NCT01813877
- Testing
- FDOPA PET/CT
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma, Liver Transplant
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current…
- Trial name
- TEP CARE (NCT04792801)
- Testing
- PET TDM FDG-Choline
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Lille
Prostate Cancer
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients
The purpose of this study is to develop a practice procedure for lymphatic drainage mapping with the intent of providing a new tool that could potentially be used for radiation treatment planning.
- Trial name
- NCT01008969
- Testing
- SPECT-CT imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Lymphoma, Hodgkin Disease
Molecular and Whole-body MR Imaging in Lymphomas
Lymphomas are classified as Hodgkin's or non-Hodgkin's lymphomas, of which especially the latter represent a heterogeneous group with varying patterns of prognosis, biological behaviour and response to treatment.
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
- Trial name
- MILY (NCT02389101)
- Testing
- 68Ga-DOTANOC PET/CT; Diffusion weighted MRI
- Where
- Finland
- Volunteers
- 21 people
- Sponsor
- Turku University Hospital
Prostate Cancer
PSMA Imaging of Localized Prostate Cancer
The present study is a phase II, open label, single-center, non-randomized, single-dose study. Twenty subjects in total will be enrolled at Weill Cornell Medical College (WCMC)/ NYPH.
- Trial name
- NCT03675451
- Testing
- 89ZR-DF-IAB2M, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Neuroendocrine Tumors
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
This is an open-label, multi-center expanded access program designed to provide access to Copper Cu 64 Dotatate for the detection, localization, and monitoring of NETs to patients that did not have access during the Phase 3 Trial.
- Trial name
- NCT04334837
- Testing
- Copper Cu 64 Dotatate
- Sponsor
- Curium US LLC
Lung Cancer, Non-small-cell Lung Carcinoma
Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers
Computed tomography (CT) images, used for radiotherapy planning, are often caught out in lung target volumes delineation because of their inability to differentiate between neoplasia, inflammation and atelectasia.
- Trial name
- PULMOTEP (NCT01421953)
- Testing
- CT-simulation and 4D PET-CT
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Bordeaux
Small Cell Lung Cancer and Breast Cancer
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v.
- Trial name
- SSTR2+ (NCT03773133)
- Testing
- Satoreotide tetraxetan, Satoreotide trizoxetan
- Where
- 8 sites in United States, Austria and 5 more
- Volunteers
- 9 people
- Sponsor
- Ipsen
Carcinoma, Non Small Cell Lung
Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis
CT-PET image fusion has the potential to differentiate 'tumor' from 'atelectasis' much better than the CT-scan in patients with non-small cell lung cancer who also have atelectasis.
- Trial name
- NCT00184964
- Testing
- CT-scan, PET-scan
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Factors Affecting BAT Activation in PET/CT
Factors Affecting BAT Activation in PET/CT
The aim of the present study is to evaluate the factors affecting BAT activation in 18F-FDG-PET/CT in different tumours
- Trial name
- NCT05577299
- Testing
- PET/CT
- Volunteers
- 80 people
- Sponsor
- Assiut University
Inflammation, Atheromatous Plaques
Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque
The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET/CT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET/CT, MRI and US and to determine the contribution of…
- Conditions
- Inflammation, Atheromatous Plaques, Carotid Artery Diseases
- Trial name
- NCT01608516
- Testing
- 68Ga-NODAGA-RGD PET/CT
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Lausanne Hospitals
Metastic Thyroid Cancer
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Background: About 5% to 10% of differentiated thyroid cancers become resistant to standard treatment with radioactive iodine. In these cases, treatment options are limited and generally not effective.
- Trial name
- NCT04927416
- Testing
- 68-Gallium-DOTATATE-PET/CT
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn's Disease
Evaluation of PET CT in the Management of Patients With Crohn's Disease.
18F-FDG PET/CT (2-[fluorine-18] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body.
- Trial name
- NCT00731809
- Testing
- FDG PET CT
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rabin Medical Center
Prostate Cancer (Diagnosis)
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
Prostate cancer is one of the most common malignancies in men. Currently, due to the limited diagnostic accuracy of existing imaging tests, there is a risk of missed diagnosis or unnecessary prostate biopsy.
- Trial name
- NCT07690306
- Where
- 6 sites in United States, China
- Volunteers
- 1,500 people
- Sponsor
- Xiangya Hospital of Central South University
Lung Cancer
Early Lung Cancer Detection in High Risk Individuals
The MILD project is a randomized lung cancer screening trial whose primary aim is to evaluate the impact on mortality of early lung cancer detection through LDCT (low-dose computed tomography) in 2 groups: a control group…
- Trial name
- MILD (NCT02837809)
- Testing
- Low dose CT
- Where
- Italy
- Volunteers
- 4,099 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Osteo Arthritis
Bone Forming at Prosthetic Surfaces. Fingerprint2
What is the intensity of F-PET uptake in healthy and osteo arthritic femur and acetabulum, compared to the uptake adjacent to four analyzed endoprosthetic components 1½ and 6 months after surgery?
- Trial name
- NCT01623687
- Testing
- Component for acetabulum (Regenerex RingLoc cup), Components for the acetabulum (Lubinus cross linked cup), Arthroplasty components are for the femur (Cemented Lubinus SP II stem)
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Uppsala University
Metastatic Prostate Cancer
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of [18F]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .
- Trial name
- NCT04528199
- Testing
- [18F]FLOR (FC303) Injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.